Hypertension Clinical Trials
There are 922 actively recruiting hypertension clinical trials across 97 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 4, Phase 1, Early Phase 1. Top locations include Boston, Massachusetts, United States, Chicago, Illinois, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.
Hypertension Trials at a Glance
922 actively recruiting trials for hypertension are listed on ClinicalTrialsFinder across 6 cities in 97 countries. The largest study group is Not Applicable with 391 trials, with the heaviest enrollment activity in Boston, Chicago, and Beijing. Lead sponsors running hypertension studies include University of Alabama at Birmingham, Vanderbilt University Medical Center, and Mayo Clinic.
Browse hypertension trials by phase
Top cities for hypertension trials
Treatments under study
Understanding Hypertension Clinical Trials
The SPRINT trial, published in 2015, reshaped hypertension management by showing that targeting a systolic blood pressure below 120 mmHg — rather than the then-standard 140 mmHg — reduced cardiovascular events and death by 25%, leading to updated treatment guidelines worldwide. Chlorthalidone, losartan, amlodipine, and essentially every major blood pressure medication in use today was established through clinical trials over the past several decades. Current hypertension trials are now tackling persistent challenges including treatment-resistant hypertension, medication adherence, renal denervation as a device-based alternative, and RNA-based therapies that could control blood pressure for months with a single injection.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Hypertension clinical trials
No. While many novel therapy trials focus on resistant hypertension, there are trials for all stages of hypertension. Some trials study people with newly diagnosed hypertension, comparing first-line treatment strategies. Others focus on preventing hypertension in people with elevated blood pressure that has not yet crossed the diagnostic threshold.
Renal denervation is a minimally invasive catheter procedure that reduces the activity of nerves around the kidney arteries that contribute to high blood pressure. Clinical trials have shown it can lower blood pressure by 5-10 mmHg on average. Side effects are generally related to the catheter procedure itself and are uncommon. Long-term safety data from trials is encouraging, but the procedure is still being studied.
Some trials require a medication washout period so researchers can measure the study intervention's independent effect on blood pressure. This is done under close monitoring with frequent blood pressure checks. Other trials are add-on studies where the new treatment is tested alongside your current medications. The specific requirements will be clearly explained before enrollment.
Trials typically use standardized automated blood pressure measurement protocols to minimize variability. Many trials also require 24-hour ambulatory blood pressure monitoring at defined time points, which provides a more comprehensive picture than office readings alone. Some trials now incorporate home blood pressure monitoring with connected devices that transmit readings to the research team.
Yes. Trials also study lifestyle interventions (structured exercise programs, dietary approaches like DASH), digital health tools for medication adherence, community health worker programs, and device-based treatments like renal denervation. These non-pharmacological trials are important for developing approaches that complement or reduce the need for medication.
Showing 1–20 of 922 trials